CELLANTRATECH THERAPEUTICS
Pioneering In Vivo CAR-T Cell Therapies
CellantraTech Therapeutics is a preclinical cell-therapy biotechnology company Developing in vivo mRNA-LNPs delivery and nonviral Sleeping Beauty–Enabled Ex Vivo CAR-T approaches for solid tumors.
Our two STEAP1 CAR co-lead programs pursue complementary therapeutic routes: mRNA-r27, a transient in vivo CAR-T program, and CAR-ST027, a durable ex vivo autologous CAR-T program use S100X to modify T cells.
ABOUT CELLANTRATECH THERAPEUTICS
Building a New Generation of CAR T-Cell Therapies
CellantraTech is developing a reusable targeted LNP delivery platform for T-cell programming, together with complementary in vivo and ex vivo therapeutic approaches.
Our lead programs are built around STEAP1-targeted CAR-T biology, while GUCY2C CAR and KRAS G12D TCR programs expand the platform into additional solid-tumor targets.
“The product is the integrated system — delivery, therapeutic payload and development architecture working together.”
OUR DEVELOPMENT APPROACH
Evidence-Gated Development from Delivery to Function
We advance programs through a common validation framework designed to address key biological, delivery, safety and product-quality questions before moving to the next stage.
01.
Target Access
Confirm target recognition, specificity and accessibility in the relevant disease setting.
02.
Delivery & Expression
Demonstrate targeted cellular uptake, payload integrity and productive CAR or TCR expression.
03.
Function & Safety
Establish disease-relevant activity while evaluating specificity, off-target activity and normal-tissue safety.
04.
Reproducibility
Confirm consistent performance across experiments, donors and relevant biological conditions.
05.
Product Quality
Build identity, integrity, consistency, stability and fit-for-purpose analytical controls into development.
06.
Decision Discipline
Advance, redesign or stop programs based on integrated experimental evidence.
OUR PLATFORM
A Reusable Nonviral Platform for T-Cell Programming
Our platform combines targeted lipid nanoparticle delivery with CAR and TCR payloads to create multiple paths for engineering therapeutic T cells.
Targeted In Vivo Delivery
CD8-targeted tLNPs are designed to deliver CAR- or TCR-encoding mRNA directly to T cells inside the body.
Two STEAP1 CAR Co-Leads
mRNA-r27 — transient in vivo STEAP1 CAR-T CAR-ST027 — permanent ex vivo autologous STEAP1 CAR-T
Nonviral SLEEPING BEAUTY-Enabled Ex Vivo CAR-T Manufacturing
CAR-ST027 uses an SLEEPING BEAUTY sb100X genome-editing approach designed to enable permanent STEAP1 CAR engineering without viral vectors or electroporation.
Pipeline Expansion
GUCY2C-targeted CAR and KRAS G12D-targeted TCR programs are ongoing preclinical expansion programs built on the same broader delivery and development capabilities.
CURRENT PRIORITIES
Advancing the STEAP1 Co-Lead Programs
STEAP1 CAR activity has been verified in vitro, with organoid assay criteria passed. Current development is focused on translating this biological validation into route-specific evidence for the two co-lead programs.
For mRNA-r27, priorities include biodistribution, productive T-cell delivery, CAR expression and in vivo safety.
For CAR-ST027, priorities include viable stable CAR-positive cell yield • integration profile and copy number • transposase clearance • reproducibility • potency • safety
GUCY2C CAR and KRAS G12D TCR remain ongoing preclinical expansion programs following in-silico validation.
All programs are preclinical. Current findings do not establish clinical efficacy, human safety or regulatory readiness.
